Janssen Submits sNDA for Spravato CIII Nasal Spray for the Rapid Reduction of Depressive Symptoms in Adults with Major Depressive Disorder and Active Suicidal Ideation with Intent

Janssen Submits sNDA for Spravato CIII Nasal Spray for the Rapid Reduction of Depressive Symptoms in Adults with Major Depressive Disorder and Active Suicidal Ideation with Intent

Janssen announced the submission of a supplemental New Drug Application (sNDA) to the U.S. FDA seeking a new indication for Spravato (esketamine) CIII nasal spray for the rapid reduction of depressive symptoms in adult patients with major depressive disorder (MDD) who...

Pin It on Pinterest